Available IPD datapackage for study 'A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer'

Name: Available IPD datapackage for study 'A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer'
Creator: Vivli
Published: 2023-05-18T14:31:06+08:00

DataCite Commons2025-01-06 更新2026-05-07 收录

前列腺癌临床试验

药物疗效评估

数据链接：

https://search.vivli.org/doiLanding/dataPackages/PR00006462.0 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).

提供机构：

Vivli

创建时间：

2023-05-18